May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Latanoprost and Usual Care in Patients With Glaucoma or Ocular Hypertension: A 36-Month, Randomized, Open-Label Study in Sweden and Finland
Author Affiliations & Notes
  • B. Fristrom
    University Hospital, Linkoping, Sweden
  • H. Uusitalo
    University of Tampere, Tampere, Finland
  • S. Forsman
    Pfizer AB, Sollentuna, Sweden
  • E. Berglund
    Pfizer AB, Sollentuna, Sweden
  • Footnotes
    Commercial Relationships  B. Fristrom, Pfizer, C; H. Uusitalo, Pfizer, C; S. Forsman, Pfizer, E; E. Berglund, Pfizer, E.
  • Footnotes
    Support  Research supported by Pfizer Inc.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1225. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B. Fristrom, H. Uusitalo, S. Forsman, E. Berglund; Latanoprost and Usual Care in Patients With Glaucoma or Ocular Hypertension: A 36-Month, Randomized, Open-Label Study in Sweden and Finland. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1225. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To compare time on therapy, efficacy, safety, and costs of latanoprost or usual care over 36 months in patients needing a change in intraocular pressure (IOP)-lowering therapy.

Methods: : This open-label, multicenter study (19 sites in Sweden; 7 in Finland) included adults with ocular hypertension or primary open-angle, exfoliative, or pigmentary glaucoma whose intraocular pressure (IOP) was uncontrolled with monotherapy. Patients with mean diurnal IOPs ≥21 mmHg were randomized (1:1) to latanoprost or usual care (commercially available therapy except a prostaglandin analog) and followed (8 visits) over 36 months. Endpoints included time to treatment failure (change in/addition to study treatment), efficacy (diurnal IOP measured at months 6, 12, 24, and 36), safety, and direct costs to treat glaucoma/other ocular conditions. Unit costs (2006) from Sweden and Finland were applied to pooled resource utilization data; total direct costs and costs of hospitalizations, ocular surgical procedures, medications, and out-patient health care resource use were calculated.

Results: : In all, 326 patients received ≥1 dose of latanoprost (n=162) or usual care (n=164). Median time to treatment failure was 3 times longer for latanoprost than usual care (36 vs 12 months, P<0.001 [log rank test]); 36-month success rates were 51.2% and 23.8%, respectively (P<0.001). Decreases from baseline in mean diurnal IOP levels were greater for latanoprost at months 6, 12, 24, and 36 (P<0.01 for all [ANCOVA]). Least squares mean reductions±SEM from baseline to month 36: latanoprost, -4.9±0.3 mmHg; usual care, -4.4±0.4 mmHg (95% CI for between-group difference: -1.8,-0.4; P=0.003; n=127). No serious adverse events were judged to be treatment related. Average total direct costs were similar in patients treated with latanoprost and usual care, but out-patient resource utilization and costs were higher for usual care-treated patients in Sweden.

Conclusions: : In patients who had failed previous treatment, time on therapy was significantly longer in those switched to latanoprost versus usual care. Latanoprost’s IOP-reducing effect and safety were sustained over 36 months, and costs generally were similar in those receiving latanoprost or usual care.

Keywords: clinical (human) or epidemiologic studies: health care delivery/economics/manpower • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • intraocular pressure 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.